Bexarotene inhibits the viability of non-small cell lung cancer cells via slc10a2/PPARγ/PTEN/mTOR signaling pathway
Abstract Background Thirty to 40 % of non-small cell lung cancer (NSCLC) patients developed higher hypertriglyceridemia in the process of treatment with bexarotene. And bioinformatics studies discovered that the expression of slc10a2 was increased in high-grade hypertriglyceridemia patients. So, we...
Na minha lista:
| Principais autores: | , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BMC
2018-04-01
|
| coleção: | BMC Cancer |
| Assuntos: | |
| Acesso em linha: | http://link.springer.com/article/10.1186/s12885-018-4224-x |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|
